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AbstrACt
Introduction Gestational diabetes mellitus (GDM) is a 
common disorder of pregnancy and contributes to adverse 
pregnancy outcomes. Metformin is often used for the 
prevention and management of GDM; however, its use 
in pregnancy continues to be debated. The Metformin 
in Pregnancy Study aims to use individual patient data 
(IPD) meta- analysis to clarify the efficacy and safety 
of metformin use in pregnancy and to identify relevant 
knowledge gaps.
Methods and analysis MEDLINE, EMBASE and all 
Evidence- Based Medicine will be systematically searched 
for randomised controlled trials (RCT) testing the efficacy 
of metformin compared with placebo, usual care or 
other interventions in pregnant women. Two independent 
reviewers will assess eligibility using prespecified criteria 
and will conduct data extraction and quality appraisal of 
eligible studies. Authors of included trials will be contacted 
and asked to contribute IPD. Primary outcomes include 
maternal glycaemic parameters and GDM, as well as 
neonatal hypoglycaemia, anthropometry and gestational 
age at delivery. Other adverse maternal, birth and neonatal 
outcomes will be assessed as secondary outcomes. IPD 
from these RCTs will be harmonised and a two- step 
meta- analytic approach will be used to determine the 
efficacy and safety of metformin in pregnancy, with a priori 
adjustment for covariates and subgroups to examine effect 
moderators of treatment outcomes. Sensitivity analyses 
will assess heterogeneity, risk of bias and the impact of 
trials which have not provided IPD.
Ethics and dissemination All IPD will be deidentified 
and studies contributing IPD will have ethical approval 
from their respective local ethics committees. This study 
will provide robust evidence regarding the efficacy and 
safety of metformin use in pregnancy, and may identify 
subgroups of patients who may benefit most from this 
treatment modality. Findings will be published in peer- 
reviewed journals and disseminated at scientific meetings, 
providing much needed evidence to inform clinical and 
public health actions in this area.
IntroduCtIon
Pregnancy is a period of major anatomic 
and physiological changes, with heightened 
metabolic demands on both mother and 
fetus. Gestational diabetes mellitus (GDM) is 
a common metabolic disorder of pregnancy 
with global prevalence estimates varying 
by country, from <1% in Croatia to 28% in 
India.1 The incidence of GDM is increasing in 
line with obesity and advanced maternal age.2 
Elevated maternal glucose concentrations and 
GDM increase the risk for adverse pregnancy 
outcomes including pre- eclampsia, macro-
somia and fetal abnormalities, and GDM 
itself is the strongest population predictor of 
type 2 diabetes (T2D).3 Increasing evidence 
suggests that fetal exposure to hypergly-
caemia in utero increases the risk of obesity 
and T2D in adulthood.4 Effective strategies 
for the prevention and/or treatment of GDM 
and its associated complications are therefore 
of paramount importance.
Metformin, a biguanide compound and 
first- line treatment for T2D, offers oppor-
tunities for preventing and treating GDM, 
although its role in pregnancy is debated due 
to the known placental transfer of metformin 
to the fetus.5 6 Metformin exerts its clinical 
effects by reducing hepatic glucose output and 
increasing insulin sensitivity, leading to lower 
strengths and limitations of this study
 ► Important area of research which will inform clinical 
practice and public health actions in this field.
 ► Protocol is for the first individual patient data (IPD) 
meta- analysis investigating metformin use in 
pregnancy.
 ► Employs rigorous methodology and a comprehen-
sive search strategy to provide the most robust ev-
idence to date.
 ► Limitations include potential for publication bias or 
data availability bias if IPD is not available for some 
studies or outcomes.
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glucose concentrations without an increased risk of hypo-
glycaemia or weight gain.3 Although metformin crosses 
the placenta, to date it has been shown to be safe, generally 
well- tolerated and preferred by women over insulin.7 8 In 
the UK and New Zealand, clinical guidelines recommend 
the use of metformin as initial glucose- lowering treat-
ment in women with GDM if lifestyle interventions are 
unsuccessful in maintaining glycaemic targets.9 However, 
in Australia and the USA, lifestyle and insulin remain the 
mainstay for GDM therapy and metformin is used on a 
case- by- case basis at the clinician’s discretion.5 6 Concerns 
around the use of metformin in pregnancy include a 
lack of conclusive evidence regarding its efficacy and 
safety for preventing or treating GDM. Despite many 
published studies over the last four decades, there have 
been no placebo- controlled trials with GDM or glucose 
regulation as the primary endpoint. This is an important 
gap in the evidence given that introducing a medication 
or treatment in pregnancy can have a powerful placebo 
effect. Also more recently, a number of follow- up studies 
have suggested potential longer term adverse child health 
implications of metformin use in pregnancy, although 
confirmation of these effects requires further study.10
Regarding the use of metformin for the treatment 
of GDM, early observational studies by Coetzee and 
colleagues5 11 12 in South Africa showed that metformin 
improved glycaemic control in women with GDM and 
subsequently reduced fetal anomalies and perinatal 
mortality. However, controversies regarding whether 
metformin was a safe and viable option for the treat-
ment of GDM continued. This was particularly relevant 
in the context of poorly resourced countries where low 
health literacy and high costs of insulin are problem-
atic.5 6 In 2008, Rowan et al13 published the landmark 
‘Metformin in GDM’ (MiG) trial and found that, in 751 
women randomised to metformin or insulin, there were 
no differences in the primary outcome—a composite 
of neonatal hypoglycaemia, respiratory distress, need 
for phototherapy, Apgar score <7 at 5 min and preterm 
birth. Secondary outcomes including neonatal anthro-
pometry also did not differ between groups; however, 
severe neonatal hypoglycaemia (<1.6 mmol/L) was 
reduced with metformin compared with insulin.13 It 
should be noted that 46.3% of women in the metformin 
group required supplemental insulin treatment to main-
tain glycaemic control.13 A large number of randomised 
controlled trials (RCT) and meta- analyses have since 
been published, with many showing that, particularly in 
cases of mild GDM, metformin is as effective as insulin 
in controlling GDM and preventing fetal, maternal and 
neonatal complications.7 14–27 Yet, some have reported 
that metformin increased the risk of preterm birth 
compared with insulin,7 while others found a decreased 
risk of pregnancy- induced hypertension,20 27 neonatal 
death or serious comorbidity14 with metformin compared 
with insulin or other oral hypoglycaemic drugs. Ongoing 
trials which are sufficiently powered, such as the 
SUGAR- DIP trial28 which aims to recruit 810 women with 
GDM, should be able to shed some light on the impact of 
metformin on some of these pregnancy outcomes.
In addition to treating GDM, the potential role of 
metformin as a GDM prevention strategy has also been 
proposed. Evidence regarding metformin exposure in 
early pregnancy and its role in GDM prevention began 
developing when metformin use became more common 
in the treatment of polycystic ovary syndrome (PCOS). 
However, observational studies (primarily retrospec-
tive), RCTs and meta- analyses in women with PCOS 
have produced conflicting findings. Some report that 
metformin reduced the risk of GDM, early pregnancy 
loss, preterm delivery and pre- eclampsia,29–34 and others 
report no effects on some or all of these outcomes.29 35 36 
Most of these studies were designed to assess metformin 
use for ovulation, pregnancy rates and live births rather 
than for pregnancy complications, and existing meta- 
analyses have been of variable quality. A recent study which 
combined three RCTs totalling 800 women with PCOS 
randomised to metformin or placebo during pregnancy 
did not show any improvement in glucose homeostasis or 
reduction in GDM or need for insulin therapy, despite the 
lower gestational weight gain in the metformin group.37 
Notably, exposure to metformin in early pregnancy was 
not associated with teratogenic effects or increased risk of 
miscarriage in any of these studies to date, or in a recent 
case–control study of >50 000 babies with congenital 
anomalies.8
Use of metformin for preventing GDM has also been 
explored in recent RCTs of overweight or obese non- 
diabetic pregnancies.38–40 Two trials in the UK38 40 exam-
ined metformin versus placebo in obese pregnancies, 
while the GRoW trial in Australia39 examined whether 
the use of metformin as an adjunct therapy to dietary and 
lifestyle advice in overweight or obese pregnancies was 
effective in improving maternal, fetal and infant health 
outcomes. All three trials reported that metformin had no 
effect on the primary outcome of neonatal birth weight 
compared with placebo,38–40 despite reduced gestational 
weight gain with metformin in two trials.39 40 No effects 
on glycaemic outcomes including incidence of GDM 
were found; however, none of the trials were powered to 
detect differences in these outcomes.38 40 Another RCT 
in non- diabetic women with pregestational insulin resis-
tance reported no effect of metformin in the prevention 
of GDM compared with placebo.41 The relatively small 
sample size (n=111) and high dropout rate (23%) may 
have influenced these results.41
Overall, there is substantial heterogeneity in the 
designs, participant characteristics and methodological 
rigour of existing studies, precluding firm conclusions 
regarding the efficacy and safety of metformin use in 
pregnancy. Although several meta- analyses have been 
conducted, most have targeted women with PCOS and all 
have used aggregate data, which may be subject to ecolog-
ical bias and study- level confounding. Here, we aim to 
address these knowledge gaps by conducting a compre-
hensive systematic review incorporating meta- analyses of 
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Table 1 PICO for study inclusion
Population (P) Intervention (I) Comparison (C) Outcomes (O)
Inclusion Pregnant women of 
any age, ethnicity, 
socioeconomic 
status, geographic 
area, comorbidity or 
gestational age
Metformin administered 
in any form and route, 
alone or combined with 
other intervention/s, of 
any dosage and for any 
duration
Placebo, usual care and/
or other pharmacological 
or non- pharmacological 
interventions including 
insulin, lifestyle 




Primary maternal outcomes: 
glycaemic control (glucose, 
insulin, HbA1c); incidence 
of GDM* and/or hyper/
hypoglycaemia*
Primary neonatal outcomes: 
hypoglycaemia*, birth 
weight, birth length, head 
circumference and gestational 
age at delivery
Secondary outcomes: 
other maternal, birth and 
neonatal outcomes including 
miscarriage, birth defects, 
GWG, pre- eclampsia/
eclampsia, LGA/macrosomia, 
SGA and PTB (see full list 
in online supplementary 
material)
Exclusion Studies in non- 
pregnant populations
Studies without a 
metformin therapy arm
Studies without a control or 
comparison arm
Studies without clinical 
outcomes (mechanistic 
studies)
Study type RCTs and systematic reviews of RCTs
Language No limit
Year of publication No limit
*As defined by authors and using the criteria selected in individual studies.
GDM, gestational diabetes mellitus; GWG, gestational weight gain; HbA1c, haemoglobin A1c; LGA, large for gestational age; PTB, preterm 
birth; RCT, randomised controlled trial; SGA, small for gestational age.
individual patient data (IPD). Using these data, we will test 
the hypothesis that metformin in pregnancy is a safe and 
effective strategy for improving maternal and neonatal 
glycaemic outcomes. Use of IPD will allow adjustment 
for differences in participant characteristics including 
maternal demographics, baseline glucose concentrations 
and use of supplemental insulin, and it can also identify 
subgroups of women who may benefit from metformin 
treatment in pregnancy.
MEthods And AnAlysIs
This review will adopt rigorous international gold stan-
dard methodology as outlined in the Cochrane Library 
and Centre for Evidence- Based Medicine (EBM) guide-
lines,42 43 and will conform to the standards of the 
Preferred Reporting Items for Systematic Reviews and 
Meta- analyses of IPD (PRISMA- IPD) statement.44 The 
protocol for this systematic review will be registered on 
PROSPERO prior to commencing the data analysis. The 
specific research question addressed by this review is as 
follows:
Is metformin use in pregnancy effective and safe versus 
placebo, usual care or other pharmacological or non- 
pharmacological interventions in:
A. Women with GDM for improving glycaemic, maternal 
and/or neonatal adverse outcomes?
B. Women without GDM for improving glycaemic, mater-
nal and/or neonatal adverse outcomes?
Eligibility criteria
Selection criteria established a priori using the Popula-
tion, Intervention, Comparison, Outcomes framework in 
table 1 will be used to determine the eligibility of studies.
search strategy
A systematic search will be developed using relevant 
search terms (online supplementary material) in accor-
dance with the selection criteria (table 1), and the 
following electronic databases will be searched:
 ► MEDLINE via OVID.
 ► MEDLINE in process and other non- indexed citations 
via OVID.
 ► EMBASE via OVID.
 ► All EBM Reviews via OVID incorporating: the Cochrane 
Library; Cochrane Database of Systematic Reviews 
(Cochrane Reviews); Database of Abstracts of Reviews 
of Effects (Other Reviews); Cochrane Central Register 
of Controlled Trials (Clinical Trials); Cochrane Data-
base of Methodology Reviews (Methods Reviews); the 
Cochrane Methodology Register (Methods Studies); 
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Table 2 Data to be extracted in aggregate and IPD format from included studies
Study Participants Intervention/control Primary outcomes† Secondary outcomes
First author and 
journal/source
Maternal age, 
parity, ethnicity and 
gestational age at 
enrolment
Metformin treatment 
protocols (dose, including 
graded dosing, frequency, 
duration)
Maternal glycaemic control 
(fasting and postprandial/
postchallenge glucose; insulin; 
and HbA1c) at any/all timepoints
All other maternal, 
birth and neonatal 
outcomes reported in 
individual studies (online 
supplementary material)
Country 





Regimens for each control 
or comparator group
Incidence of GDM* and/or 
maternal hyper/hypoglycaemia*





Smoking status and 
use of medications, 
supplements or 
substances
Use of supplemental 
insulin
Incidence of neonatal 
hypoglycaemia*
Development of T2D 




Disease status (pre- 
existing T2D, GDM, 
PCOS, and so on)




Birth weight, birth length and 
head circumference, and 
gestational age at delivery*







history of GDM or 
family history of 
diabetes
Number analysed per 
group and ITT analysis
  Adverse events/side 




        
*As defined by authors of individual studies which may be based on clinical diagnosis (separate analyses will be performed for different GDM 
diagnostic criteria) or in the case of gestational age, this may be based on ultrasound measurements, last menstrual cycle, self- report, and so 
on.
†Baseline, follow- up and delta values will be collected for all continuous primary maternal outcomes.
BMI, body mass index; GDM, gestational diabetes mellitus; GWG, gestational weight gain; HbA1c, haemoglobin A1c; IPD, individual patient 
data; ITT, intention to treat; PCOS, polycystic ovary syndrome; T2D, type 2 diabetes.
Health Technology Assessment Database (Technology 
Assessments); NHS Economic Evaluation Database 
(Economic Evaluations); and ACP Journal Club.
Bibliographies and citations of all relevant studies 
identified by the search strategy and relevant reviews/
meta- analyses will be examined for identification of addi-
tional studies. Google will be used to manually search 
for grey literature (ie, material not published in recog-
nised or indexed scientific journals). Unpublished or 
ongoing studies will be identified via manual searching 
of the National Institute of Health Clinical Trials Registry 
(https:// clinicaltrials. gov/) and the Australian New 
Zealand Clinical Trials Registry (https://www. anzctr. org. 
au).
study selection
To determine eligible studies, one reviewer will scan the 
titles, abstracts and keywords of every record retrieved by 
the search strategy using the selection criteria outlined 
in table 1 and in consultation with a second reviewer. 
Disagreement will be resolved by discussion and 
consensus, otherwise referred to a third reviewer. All arti-
cles which appear to meet the selection criteria will be 
retrieved for full- text assessment, and articles with insuf-
ficient information in the titles and abstracts will also be 
retrieved in full text to clarify eligibility. Studies excluded 
based on full text will be recorded with reasons for their 
exclusion.
data extraction
Using a specifically developed data extraction form, 
two independent reviewers will extract data from all 
included studies. Pilot testing of the extraction form 
will be conducted using three to four studies to ensure 
all required data are captured. Computed data entries 
will be cross- checked for meta- analyses where required. 
Prespecified data will be extracted in aggregate format 
from all published studies (table 2). Relevant data will 
also be requested in IPD format from all authors along 
with any study or treatment protocol details not reported 
in published studies (table 2).
Aggregate data extraction
For each treatment group, extracted data will include 
sample sizes, aggregate point estimates and measures of 
variability, frequency counts for dichotomous variables 
and intention- to- treat analysis. For outcomes reported as 
continuous variables, the aggregate mean values with SDs 
or CIs will be extracted and used to measure the effects. 
Where SEs are reported, these will be converted to SD 
using the formula:  SE ×
√
n  . For outcomes reported 
as dichotomous variables, relative measures of risk (risk 
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ratio or OR along with CIs), or absolute numbers of 
patients experiencing at least one episode of the outcome 
of interest will be extracted and used in the analyses.
IPD collection
Corresponding and/or lead authors will be contacted 
and asked to provide fully anonymised data for IPD 
meta- analyses. Data for participant characteristics and 
primary and secondary outcomes (as specified in table 2 
and online supplementary material) will be requested for 
each patient, in addition to data on supplemental insulin 
use (or other cointerventions) if individual- level data for 
these parameters were recorded. These data will be used 
to conduct stratified and subgroup analyses at the patient 
level, in particular by baseline body mass index (BMI) and 
baseline glucose concentrations, as well as by maternal 
age, parity, ethnicity, history of GDM, gestational weight 
gain and supplemental insulin use.
A formatted template detailing the requested data 
and recommended coding will be created and sent to 
authors; however, data will be accepted in any suitable 
electronic format. All data will be checked to ensure 
correct coding, consistency with published results and 
accuracy of extreme values and to identify missing data, 
and any issues will be queried and rectified as necessary. 
A single database will be created by the study investiga-
tors to incorporate data from all trials in consistent fields 
and standardised formats (as much as possible). Studies 
which are excluded or where IPD is not available will be 
tabulated with reasons, and aggregate data will be used 
where appropriate.
Quality appraisal of the evidence
Risk of bias of included studies will be assessed at the 
study level by two independent reviewers. Using a critical 
appraisal template 45 (adapted from the Cochrane risk of 
bias tool 46) with predetermined criteria, each study will 
be allocated a high, moderate or low risk of bias rating. 
Individual quality items will be assessed using a descriptive 
component approach that includes items such as conflict 
of interest of authors, presence of prespecified selec-
tion criteria, methods of randomisation and allocation 
of participants to study groups, blinding of participants, 
carers, investigators or outcome assessors, methods of 
outcome assessment and reporting, and statistical issues 
such as powering and methods of data analysis. Disagree-
ment will be resolved by consensus.
data analysis and synthesis
Our IPD analysis will follow a two- step meta- analytical 
approach where possible to automatically account 
for clustering of participants within studies.47 In this 
approach, IPD analyses will be conducted to generate esti-
mates of the intervention effect for each study separately. 
These effect estimates will then be pooled and analysed 
using conventional meta- analyses with inverse- variance 
weighted models (DerSimonian and Laird random 
effects models) to account for between- study variability.47 
Where IPD is derived from a small number of studies or 
for binary outcome data where the event risk is low or 
the sample size is small, a one- step IPD approach will be 
used (IPD from all studies are modelled simultaneously). 
Stratified analysis by study will be performed to account 
for participant clustering in the one- step approach.47 48 
If IPD is only available for some studies, we will combine 
aggregate data with the available IPD to compare results 
from analyses including and excluding IPD.49 50 This 
approach will allow the effect of non- IPD studies on meta- 
analysis conclusions to be quantified and displayed trans-
parently. For outcomes with no IPD available, aggregate 
effect measures and random effects models will be used 
for meta- analyses where appropriate, provided that data 
are derived from clinically homogeneous groups (where 
participants, interventions and outcome measures are 
sufficiently similar).
Dichotomous outcomes will be presented as relative 
risks/risk ratios with 95% CIs and continuous outcomes 
will be presented as weighted mean differences with 95% 
CIs. Where outcome measures or study methods differ 
substantially, data will be analysed in line with Cochrane 
guidelines,42 using random effects models and Cohen’s d 
to calculate the standardised mean difference. All meta- 
analyses will be conducted on Review Manager V.5.3 and 
IPD data will be initially analysed in Stata V.15 and then 
imported into Review Manager. Comprehensive Meta- 
Analysis V.3 software will be used for meta- regression (if 
applicable) and assessment of publication bias. P values 
<0.05 will indicate statistical significance. Statistical 
heterogeneity will be assessed using the I2 test, where I2 
values over 50% will be considered as moderate to high 
heterogeneity. Descriptive analyses will be conducted for 
those studies which are deemed clinically heterogeneous 
or present insufficient IPD or aggregate data for pooling.
Subgroup and sensitivity analyses
Subgroup analyses and, where applicable, multivariable 
meta- analyses or meta- regression will be performed for 
factors presumed to cause heterogeneity or variations 
in outcomes. Prespecified variables to be accounted for 
will include maternal age, ethnicity, comorbidity/disease 
status, baseline BMI and glucose concentrations, history 
of GDM or other relevant pregnancy complication/s, 
dose and duration of metformin therapy, use of supple-
mental insulin and gestational age at commencement 
of therapy. These variables were selected on the basis of 
evidence showing that the benefits of metformin therapy 
may vary by these factors.51–53 Diagnostic criteria for GDM 
will also be explored for studies measuring incidence of 
GDM as an outcome. The exact variables to be explored 
will be selected after data collation but prior to any anal-
yses and will be justified by biological reasoning. Caution 
will be used in interpretation of subgroup results and 
adjustment for multiple testing will be considered as 
necessary. IPD meta- analyses generally have increased 
power to detect genuine subgroup effects; however, we 
will assess whether subgroup effects are consistent within 
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individual studies, if deemed necessary. Any post hoc 
subgroup analyses will be considered hypothesis gener-
ating for the purpose of planning and designing future 
studies. Meta- regression and/or multivariable meta- 
analyses using linear or logistic regression estimates will 
be used where appropriate to adjust for the above covari-
ates and to synthesise multiple interaction estimates from 
each study, accounting for their correlations.
Sensitivity analyses will be conducted and factors to be 
included will be determined during the review process. 
Heterogeneity (I2>50%) will be explored through sensi-
tivity analysis using risk of bias and IPD availability. For 
IPD and aggregate meta- analyses incorporating more 
than three studies, funnel plot asymmetry and Egger54 
and Begg55 statistical tests will be used to determine small 
study effects and potential publication bias.56 57
Grading the body of evidence
Quality of the evidence will be assessed at the outcome 
level by two independent reviewers and rated as high, 
moderate, low or very low using the Grading of Recom-
mendations Assessment, Development and Evaluation 
approach.58 These ratings will be based on risk of bias, 
imprecision, heterogeneity, indirectness and suspicion of 
publication bias. Availability of IPD and presence of selec-
tion or publication bias for IPD studies will also be incor-
porated into quality assessments in line with PRISMA- IPD 
guidelines.44 Disagreements will be resolved by discussion 
and consultation with a third reviewer where needed.
Presentation of findings
Data will be presented in summary tables and in narra-
tive format to describe the populations, interventions and 
outcomes of the included studies. Forest plots and funnel 
plots will be used to present results from meta- analyses 
and publication bias assessments, respectively. Where 
necessary, results with and without IPD will be presented 
for comparison. Both aggregate and IPD meta- analyses 
processes, including results, will be reported according to 
PRISMA59 and PRISMA- IPD44 guidelines.
EthICs And dIssEMInAtIon
Ethical approval is not required for aggregate data meta- 
analyses. Individual trials contributing primary data for 
IPD meta- analyses will have ethical approval from their 
respective Human Research Ethics Committees in the 
countries where the studies took place. All data from 
primary trials will be fully anonymised prior to being 
imported into our database.
Findings will be disseminated via publications in peer- 
reviewed journals and presentations at scientific meetings. 
If deemed appropriate, findings will also be communi-
cated at meetings and forums to relevant stakeholders to 
guide clinical practice and public health actions in this 
area.
data availability statement
No data have been generated or analysed in this 
manuscript.
Patient and public involvement statement
It was not appropriate or possible to involve patients or 
the public in the design, or conduct, or reporting, or 
dissemination plans of our research.
dIsCussIon
GDM is one of the most common complications of preg-
nancy and contributes to adverse perinatal outcomes, 
as well as long- term risk of obesity and T2D in the 
offspring.60 Although metformin is often prescribed 
(in addition to lifestyle intervention) in the clinical 
treatment of GDM, its efficacy and safety in pregnancy 
continues to be debated.9 61 Recent RCTs have provided 
much needed evidence in this field; however, hetero-
geneity in study designs, participant characteristics and 
methodological quality have made it difficult to draw 
firm conclusions from the available evidence. Moreover, 
whether metformin may be beneficial in women without 
GDM for the prevention of glycaemic and other adverse 
outcomes remains uncertain.
To the best of our knowledge, this will be the most 
comprehensive systematic review investigating the use 
of metformin for preventing or treating GDM and other 
pregnancy complications. It is also the only review in 
this area to incorporate an IPD meta- analysis examining 
whether the effects of metformin, if any, are indepen-
dent of potential confounders and whether they may be 
specific to certain subgroups of women. Our systematic 
review process has several strengths, including the use of 
rigorous methodology, prespecified criteria and prede-
termined primary and secondary outcomes in order to 
establish the efficacy and safety of metformin in a variety 
of population groups. The IPD component of this study 
will involve acquiring, cleaning, standardising and synthe-
sising raw data from existing studies. Although this is 
an intensive process, it is more feasible and less costly 
than large- scale RCTs and avoids the ethical problem of 
research waste,62 thus it is considered the gold standard 
approach to evidence synthesis.44 This approach is partic-
ularly important in reviewing controversial therapeutic 
areas and can provide level 1 evidence to guide clinical 
practice.44
In contrast to standard aggregate data meta- analysis, 
using individual- level data enables a more detailed assess-
ment of risk of bias and, more importantly for this study, it 
provides more power to detect subgroups of interest and 
to examine effect modifiers at the individual level, which 
would otherwise require a very large and costly clinical 
trial.63 Aggregate data, while useful, are often reported 
poorly, inconsistently (ie, using different measures) or 
selectively according to which results are significant, 
further amplifying the problems of publication bias and 
selective reporting.64 Here, the use of IPD will allow us 
to: standardise the data (eg, of timepoints, units, anal-
ysis methods, and so on); use consistent exclusion and 
inclusion criteria; directly extract data in the required 
format and deal with missing data appropriately; adjust 
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for baseline (prognostic) factors and individual risk status 
consistently across studies to increase power and account 
for potential confounders; and examine complex rela-
tionships, multiple timepoints and multiple individual- 
level factors and their interactions.64
Potential limitations should be noted. First, IPD meta- 
analyses are no panacea against poorly designed and 
conducted primary research. Thus, the strength of the 
evidence and conclusions drawn from this meta- analysis 
will depend on the quality of included trials and their 
data availability. Second, although we will endeavour to 
identify grey literature and unpublished data as part of 
the search strategy, publication bias cannot be ruled out. 
Finally, there is potential for data availability bias if IPD 
are unavailable for some studies and this influences our 
results. To counter this and ensure transparency, we will 
report findings from meta- analyses with and without IPD 
and we will contact authors to initiate collaboration and 
to seek data- sharing agreements to access anonymised 
data from major trials.
Given the impact of GDM on adverse pregnancy 
outcomes and the long- term health of both mother and 
offspring, putting in place simple and effective strategies 
for prevention and management is crucial. This IPD meta- 
analysis will provide the most robust evidence to date as 
to whether metformin is an effective and safe therapy for 
use in pregnancy and may identify specific subgroups 
of patients who may benefit most from this treatment 
modality. Findings from this meta- analysis will provide 
much needed evidence to inform appropriate evidence- 
based clinical and public health actions in this area.
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